Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of bosentan on morbidity and mortality in idiopathic pulmonary fibrosis
2006-001183-24Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing bosentan with placebo (2 arms). Primary endpoint: Time to disease worsening or death. Started Nov 2006; status: completed.
02
Drugs
bosentan
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2006-001183-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001183-24.